Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

June 30 June 30 ------- ------- 2009 2008* 2009 2008* ---- ---- ---- ---- Revenue, net Actimmune $7,110 $7,296 $13,142 $15,792 Collaboration revenue 818 818 1,636 1,636 --- --- ----- ----- Total revenue, net 7,928 8,114 14,778 17,428 Costs and expenses: Cost of goods sold 1,860 2,492 4,718 5,863 Research and development 22,930 25,395 47,357 52,410 General and administrative 8,519 7,091 16,995 14,539 Acquired research and development milestone - - 13,500 - Restructuring charges 127 - 740 - --- --- --- --- Total costs and expenses 33,436 34,978 83,310 72,812 Loss from operations (25,508) (26,864) (68,532) (55,384) Interest income 498 1,272 1,167 3,432 Interest expense (2,487) (3,657) (5,220) (7,096) Loss on extinguishment of debt (9,540) (1,294) (9,540) (1,294) Other income (expense) 377 987 5,647 1,268 --- --- ----- ----- Loss from continuing operations before income taxes (36,660) (29,556) (76,478) (59,074) Income tax expense/(benefit) - - 2,194 (325) --- --- ----- ---- Loss from conti
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
(Date:12/13/2014)... CanDiag, Inc., a University of North Carolina at ... to OncoTab, Inc. , “The new name is ... said CEO and Chief Science Officer, Dr. Pinku Mukherjee, ... diagnostics to include imaging and therapies, and our new ... in 2011 by Dr. Mukherjee, an Irwin Belk Endowed ...
(Date:12/13/2014)... 2014 The “Global Synthetic Biology ... drivers, threats, opportunities, and challenges. , The global ... players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont ... jointly accounted for approximately ~65% of the total ... Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex Inc., ... discovery and development of therapeutic monoclonal antibodies ... announced publication of a manuscript entitled "SEMA4D ... remyelination in neurodegenerative disease" in the January ... Disease*.  The publication highlights an important role ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... for Consistent,Electronic Health Record for All Citizens Using ... GREAT RIVER, N.Y., Oct. 16 Netsmart ... services for health and,human services organizations, today announced ... services contract by the City and County of ...
... on InterMune Phase 3 CAPACITY Program - ... patient retention rate in CAPACITY -, BRISBANE, Calif., Oct. ... on October 16, 2008, the Japanese,Ministry of Health, Labor and ... & Co. Ltd. to market pirfenidone,for the treatment of patients ...
... a leading center for medical excellence; collaboration will focus ... biomaterials and ... grant from the John S.,and James L. Knight Foundation, five leading ... in,Akron -- a unique collaboration that will expand upon the region,s ...
Cached Biology Technology:Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 2Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4BioInnovation Institute in Akron Launched 2BioInnovation Institute in Akron Launched 3BioInnovation Institute in Akron Launched 4
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2008) Transfusion science, a discipline ... associated with blood transfusion and tissue transplantation, has made ... of an informative book in this field, Transfusion ... The first edition of Transfusion Science ...
... schizophrenia, major depression and cancer are not caused ... A novel computational biology method developed by a ... http://www.njit.edu/news/2008/2008-367.php , associate professor in NJIT,s department of ... to uncover the critical genes responsible for disease ...
... California team that developed a successful insect pest ... pesticide reduction, will be honored at the Entomological ... in Reno. The seven-member Almond Pest Management ... the Entomological Foundation,s "2008 Award for Excellence in ...
Cached Biology News:New book includes advances in the science and practice of transfusion and transplantation 2NJIT professor finds engineering technique to identify disease-causing genes 2Almond pest management team to receive major award at ESA meeting 2
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
DONOR BOVINE SERUM AND PLASMA...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: